香港股市 將收市,收市時間:1 小時 37 分鐘
  • 恒指

    20,166.45
    +381.80 (+1.93%)
     
  • 國指

    6,874.09
    +144.33 (+2.14%)
     
  • 上證綜指

    3,245.70
    +0.32 (+0.01%)
     
  • 滬深300

    4,013.45
    +13.94 (+0.35%)
     
  • 美元

    7.8491
    -0.0004 (-0.01%)
     
  • 人民幣

    0.8775
    +0.0022 (+0.25%)
     
  • 道指

    32,394.25
    -37.83 (-0.12%)
     
  • 標普 500

    3,971.27
    -6.26 (-0.16%)
     
  • 納指

    11,716.08
    -52.76 (-0.45%)
     
  • 日圓

    0.0593
    -0.0004 (-0.67%)
     
  • 歐元

    8.4986
    -0.0125 (-0.15%)
     
  • 英鎊

    9.6630
    -0.0190 (-0.20%)
     
  • 紐約期油

    73.76
    +0.56 (+0.77%)
     
  • 金價

    1,962.30
    -11.20 (-0.57%)
     
  • Bitcoin

    28,013.88
    +917.26 (+3.39%)
     
  • CMC Crypto 200

    612.96
    +370.28 (+152.58%)
     

US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines

  • The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC: COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.

  • Croda will also invest up to $58 million.

  • The investment will be used to establish a new lipid facility in Lamar, Pennsylvania. Construction is expected to start later this year, with the new capacity anticipated in 2025.

  • The investment supports the expansion of Croda's portfolio, by creating a third manufacturing site for lipid systems, alongside Croda's existing Alabaster, Alabama, U.S. (Avanti) and Leek, U.K. capabilities.

  • The cooperative agreement is a joint award from the Biomedical Advanced Research and Development Authority (BARDA), and an arm of the U.S. Department of defense will join forces for preparedness for future health emergencies.

  • Financial Times writes that Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines were the first approved jabs to be made with mRNA technology.

  • The vaccines rely on bubbles of fat known as lipid nanoparticles to deliver genetic codes that teach the immune system to recognize the virus.

  • Lipid systems offer significant potential as the delivery system for many nucleic acid applications, including novel mRNA-based therapeutics, such as flu vaccines and cancer treatments.

  • Given the current clinical development pipeline's scale, the lipid systems market is expected to grow significantly over the next ten years.

  • Image by Spencer Davis from Pixabay

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.